2cureX AB (2CUREX) - Net Assets
Based on the latest financial reports, 2cureX AB (2CUREX) has net assets worth Skr626.00K SEK (≈ $67.37K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr5.18 Million ≈ $557.02K USD) and total liabilities (Skr4.55 Million ≈ $489.65K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 2cureX AB (2CUREX) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr626.00K |
| % of Total Assets | 12.09% |
| Annual Growth Rate | -5.13% |
| 5-Year Change | -91.34% |
| 10-Year Change | N/A |
| Growth Volatility | 78.58 |
2cureX AB - Net Assets Trend (2015–2024)
This chart illustrates how 2cureX AB's net assets have evolved over time, based on quarterly financial data. See 2cureX AB (2CUREX) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for 2cureX AB (2015–2024)
The table below shows the annual net assets of 2cureX AB from 2015 to 2024. For live valuation and market cap data, see 2cureX AB (2CUREX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr5.10 Million ≈ $548.73K |
-57.78% |
| 2023-12-31 | Skr12.08 Million ≈ $1.30 Million |
-71.93% |
| 2022-12-31 | Skr43.03 Million ≈ $4.63 Million |
-42.12% |
| 2021-12-31 | Skr74.34 Million ≈ $8.00 Million |
+26.30% |
| 2020-12-31 | Skr58.86 Million ≈ $6.33 Million |
+109.66% |
| 2019-12-31 | Skr28.08 Million ≈ $3.02 Million |
+106.12% |
| 2018-12-31 | Skr13.62 Million ≈ $1.47 Million |
-32.69% |
| 2017-12-31 | Skr20.24 Million ≈ $2.18 Million |
+155.68% |
| 2016-12-31 | Skr7.91 Million ≈ $851.78K |
-3.34% |
| 2015-12-31 | Skr8.19 Million ≈ $881.25K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to 2cureX AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 150.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr2.51 Million | 49.23% |
| Other Components | Skr6.72 Million | 131.73% |
| Total Equity | Skr5.10 Million | 100.00% |
2cureX AB Competitors by Market Cap
The table below lists competitors of 2cureX AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mangoceuticals, Inc. Common Stock
NASDAQ:MGRX
|
$5.16 Million |
|
Nexgel Inc
NASDAQ:NXGL
|
$5.16 Million |
|
Alaunos Therapeutics Inc
NASDAQ:TCRT
|
$5.17 Million |
|
European Opportunities Trust plc
LSE:EOT
|
$5.17 Million |
|
YGL Convergence Bhd
KLSE:0086
|
$5.15 Million |
|
ScandiDos AB
ST:SDOS
|
$5.15 Million |
|
GRAND PEAK CAPITAL
F:6GP1
|
$5.15 Million |
|
Willow Biosciences Inc
TO:WLLW
|
$5.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 2cureX AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,078,000 to 5,099,000, a change of -6,979,000 (-57.8%).
- Net loss of 4,128,000 reduced equity.
- Share repurchases of 2,690,000 reduced equity.
- New share issuances of 2,690,000 increased equity.
- Other comprehensive income increased equity by 64,828,000.
- Other factors decreased equity by 67,679,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-4.13 Million | -80.96% |
| Share Repurchases | Skr2.69 Million | -52.76% |
| Share Issuances | Skr2.69 Million | +52.76% |
| Other Comprehensive Income | Skr64.83 Million | +1271.39% |
| Other Changes | Skr-67.68 Million | -1327.3% |
| Total Change | Skr- | -57.78% |
Book Value vs Market Value Analysis
This analysis compares 2cureX AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.90x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.55x to 7.90x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Skr0.75 | Skr1.91 | x |
| 2016-12-31 | Skr0.72 | Skr1.91 | x |
| 2017-12-31 | Skr2.27 | Skr1.91 | x |
| 2018-12-31 | Skr1.32 | Skr1.91 | x |
| 2019-12-31 | Skr2.42 | Skr1.91 | x |
| 2020-12-31 | Skr4.33 | Skr1.91 | x |
| 2021-12-31 | Skr4.53 | Skr1.91 | x |
| 2022-12-31 | Skr2.45 | Skr1.91 | x |
| 2023-12-31 | Skr0.69 | Skr1.91 | x |
| 2024-12-31 | Skr0.24 | Skr1.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 2cureX AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -80.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.52x
- Recent ROE (-80.96%) is below the historical average (-56.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -5.85% | -21.44% | 0.19x | 1.47x | Skr-1.30 Million |
| 2016 | -8.20% | -48.18% | 0.12x | 1.37x | Skr-1.44 Million |
| 2017 | -15.50% | -6672.34% | 0.00x | 1.13x | Skr-5.16 Million |
| 2018 | -53.33% | -94.64% | 0.32x | 1.76x | Skr-8.63 Million |
| 2019 | -28.26% | -66.21% | 0.32x | 1.35x | Skr-10.74 Million |
| 2020 | -12.44% | -47.56% | 0.24x | 1.07x | Skr-13.21 Million |
| 2021 | -25.47% | -256.22% | 0.09x | 1.06x | Skr-26.37 Million |
| 2022 | -69.18% | -33077.78% | 0.00x | 1.11x | Skr-34.07 Million |
| 2023 | -269.23% | -20979.35% | 0.01x | 1.35x | Skr-33.73 Million |
| 2024 | -80.96% | 0.00% | 0.00x | 1.52x | Skr-4.64 Million |
Industry Comparison
This section compares 2cureX AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $168,612,411
- Average return on equity (ROE) among peers: -26.44%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 2cureX AB (2CUREX) | Skr626.00K | -5.85% | 7.27x | $5.16 Million |
| Ascelia Pharma AB (publ) (ACE) | $237.06 Million | -16.83% | 0.06x | $41.03 Million |
| AcouSort AB (ACOU) | $376.48K | 28.69% | 1.44x | $9.52 Million |
| Active Biotech AB (ACTI) | $46.67 Million | -106.88% | 0.22x | $103.60 Million |
| Alzinova AB (ALZ) | $105.53 Million | -12.38% | 0.06x | $8.00 Million |
| AlzeCure Pharma (ALZCUR) | $233.17 Million | -15.43% | 0.02x | $46.62 Million |
| Annexin Pharmaceuticals AB (ANNX) | $15.57 Million | -63.12% | 0.51x | $9.23 Million |
| Alligator Bioscience AB (ATORX) | $41.44 Million | 0.00% | 0.15x | $11.36 Million |
| BioInvent International AB (BINV) | $49.01 Million | -36.81% | 0.66x | $163.58 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.39 Billion |
About 2cureX AB
2cureX AB (publ) operates as a medical technology company in Europe. The company's principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient's tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.